Relypsa to Present Multiple Posters at Upcoming Medical

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Relypsa to Present Multiple Posters at Upcoming Medical Meetings Highlighting Patiromer for Oral Suspension and Hyperkalemia Prevalence

REDWOOD CITY, Calif., May 15, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq: RLYP ), a biopharmaceutical company, today announced multiple poster presentations at the 2015 Annual Scientific Meeting of the American Society of Hypertension (ASH), including a late-breaking poster highlighting new data on changes to aldosterone levels from the Phase 3 OPAL-HK study of Patiromer for Oral Suspension (Patiromer FOS). Elevated aldosterone, which regulates the balance of water and electrolytes in the body by forcing the kidney to excrete potassium into the urine, is associated with the progression of chronic kidney disease and cardiovascular complications. Additionally, Relypsa will present a poster at the 20 th International Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) featuring new estimates of the prevalence of hyperkalemia in patients with advanced kidney and heart disease, as well two encore poster presentations on Patiromer FOS at the upcoming Heart Failure Association of the European Society of Cardiology Congress (HFA-ESC).

Data presented at ASH will include data from the two-part, Phase 3 OPAL-HK study, as well as data from the Phase 2 AMETHYST-DN study. Primary outcomes data from the Phase 3 OPAL-HK study were published in the New England Journal of Medicine in November 2014, and data from both trials were combined with results from Relypsa's broader clinical development program to support the Company's New Drug Application (NDA) for Patiromer FOS. The U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) action date of October 21, 2015, for completion of the review of the NDA.

"In an analysis of the Phase 3 OPAL-HK data, treatment with Patiromer FOS reduced aldosterone along with potassium levels during Part A of the study. During the Part B withdrawal phase of the study, aldosterone levels increased in placebo patients more than those treated with Patiromer FOS," said Lance Berman, M.D., chief medical officer of Relypsa. "The data suggests that Patiromer FOS may have a further positive impact on key cardiorenal comorbidities of hyperkalemia beyond the regulation of potassium levels, which could be particularly important in the chronic use setting."

2015 Annual Scientific Meeting of the American Society of Hypertension Poster Presentations:

  • Patiromer Decreases Aldosterone, With Decreases in Urine Albumin/Creatinine Ratio and Systolic Blood Pressure, in Patients with Chronic Kidney Disease and Hyperkalemia on RAAS Inhibitors: Results from OPAL-HK (Weir, et al. Late-breaking Poster #1; May 18, 2015)  
  • Reduction of Serum K+ with Patiromer for 1 Year in Patients with Diabetic CKD Who Developed Hyperkalemia While on Maximal Losartan and/or Spironolactone (Bakris, et al. Poster #126; May 17, 2015)  
  • Patiromer Increased Time to Renin-Angiotensin-Aldosterone System Inhibitor Discontinuation Compared with Placebo in Advanced Chronic Kidney Disease Patients with Hyperkalemia: Results from the Randomized Phase 3 OPAL-HK Study (Weir, et al. Poster #87; May 17, 2015)  
  • Treatment Gap Between Clinical Guidelines and the Utilization of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Chronic Kidney Disease and/or Diabetes: The Role of Hyperkalemia (Knispel, et al. Poster #9; May 16, 2015)

20th International Meeting of the International Society for Pharmacoeconomics and Outcomes Research Poster Presentation:

  Heart Failure Association of the European Society of Cardiology (HFA-ESC) Encore Poster Presentations:

  • Effect of cardiovascular comorbidities on the mortality risk associated with serum potassium (Pitt et al. Poster #P458, May 23, 2015)  
  • Patiromer lowers serum potassium and prevents recurrent hyperkalemia in patients with heart failure and CKD when treated with RAAS inhibitors: results from OPAL-HK (Pitt et al. Poster #P397, May 23, 2015)

About Hyperkalemia

Hyperkalemia, a serious condition defined as abnormally elevated levels of potassium in the blood, is frequently prevalent in patients who suffer from chronic kidney disease, hypertension, diabetes and/or heart failure. Hyperkalemia can lead to life-threatening cardiac arrhythmia and sudden death. Patients with chronic kidney disease or heart failure are at particular risk for developing hyperkalemia, especially those treated with renin-angiotensin-aldosterone-system (RAAS) inhibitors such as ARBs (Angiotensin Receptor Blockers), AAs (Aldosterone Antagonists), and ACE (Angiotensin-Converting-Enzyme) inhibitors. Although RAAS inhibition has been shown to protect kidney and cardiac function, many patients who could benefit from RAAS inhibitors are untreated or undertreated due to the undesirable side effect of increasing serum potassium.

About Patiromer FOS

Patiromer FOS is an oral potassium binder being developed for the treatment of hyperkalemia. The compound has been evaluated in CKD patients with hyperkalemia, including a two-part Phase 3 program, a 12-month Phase 2 trial and a 48-hour Phase 1 onset-of-action trial. In all of those trials, Patiromer FOS met its efficacy endpoints and the treatment was well tolerated. The pivotal clinical trial for Patiromer FOS was conducted under a Special Protocol Assessment with the FDA.

About Relypsa, Inc.

Relypsa, Inc. is a biopharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases. The company's two-part pivotal Phase 3 trial of its lead product candidate, Patiromer for Oral Suspension, for the treatment of hyperkalemia, a potentially life-threatening condition defined as abnormally elevated levels of potassium in the blood, has been completed and the primary and secondary endpoints were met. A New Drug Application for Patiromer for Oral Suspension for the treatment of hyperkalemia was accepted by the U.S. Food and Drug Administration and is currently under review. Relypsa has global royalty-free commercialization rights to Patiromer for Oral Suspension, which has intellectual property protection in the United States until at least 2030. More information is available at www.relypsa.com .

Forward Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Relypsa, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the potential approval of Patiromer for Oral Suspension, or Patiromer FOS, and the potential of Patiromer FOS to have a positive impact on key cardiorenal comorbidities of hyperkalemia beyond the regulation of potassium levels. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Relypsa's regulatory filings, Relypsa's substantial dependence on Patiromer FOS, Relypsa's commercialization plans and efforts and other matters that could affect the availability or commercial potential of Patiromer FOS. Relypsa undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Relypsa in general, see Relypsa's current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2014 and its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2015.

Alex Dobbin Associate Director, Investor Relations and Corporate Affairs 650.421.9687 IR@relypsa.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Vail Resorts Bets on Music to Deepen Epic Pass Demand

Updated Category News Views 119

A bass drop at 11,000 feet is not merely a party trick when you run 42 mountain resorts. Vail Resorts is putting live music, après programming and destination events squarely beside skiing and riding for winter 2026-27, and the business logic is pretty plain: give people another reason to buy early, stay longer and return with friends. For investors watching MTN, this is...

Continue Reading
NYSE Message Record Puts Market Plumbing Into Focus

Updated Category News Views 120

A trillion messages is not a cute little exchange statistic; it is the sort of number that tells you whether the market’s pipes can keep working when everybody starts shouting at once. NYSE says it handled a record 1.166 trillion messages in one day on November 5, roughly 4% above the prior high set amid April 2025 volatility. Better yet, according to the exchange,...

Continue Reading
LGT Middle East Win Highlights Patient Private Banking

Updated Category News Views 166

A trophy in Dubai is not a balance sheet, but it can be a useful calling card when the clientele measures relationships in decades rather than quarters. LGT Middle East was named Best Pure Play Private Bank at the WealthBriefing MENA Awards 2026, at a ceremony held in Dubai on November 18. For a family-owned wealth manager working with Middle Eastern families, that sort...

Continue Reading
Holland America Puts 2028 Alaska Demand on Display

Updated Category News Views 123

Alaska’s interior is where a cruise brochure either earns its keep or gets exposed. Holland America Line is opening bookings for 2028 Alaska Cruisetours nearly two years ahead, tying a coast-and-land product to the reimagined Oosterdam’s Alaska debut. That is not merely another itinerary release. It is a fairly deliberate attempt to sell a bigger, longer and...

Continue Reading
New York's $1.2M Prison Abuse Deal Raises State Stakes

Updated Category News Views 30

One courtroom result can expose a whole warehouse of institutional neglect, and this one lands with a grim thud. New York has agreed to pay $1.2 million to resolve a claim involving sexual assault by a former corrections officer at Bayview Correctional Facility in Manhattan. The settlement came after a two-week Adult Survivors Act bellwether trial concluded on November 17...

Continue Reading
Africa’s Digital Leap Still Has a 64% Usage Problem

Updated Category News Views 100

A continent can be blanketed in signal and still feel digitally stranded. That is the stubborn fact sitting inside the GSMA Digital Africa Index 2026: mobile broadband reaches 92% of Africa’s population, while only 28% use mobile internet on their own devices. The 64% usage gap is not a rounding error or a tidy policy footnote. It is the whole unfinished job. From an...

Continue Reading
SciBase Sets Its 2027 AGM Nominating Committee Early

Updated Category News Views 94

Four names on a committee roster rarely make anyone pound the table, and they should not. Still, SciBase Holding has put an important bit of corporate housekeeping in place for its 2027 Annual General Meeting: the nominating committee that will handle shareholder-facing governance work ahead of the May 20 meeting in Stockholm. For a small listed medical-technology...

Continue Reading
Ajman Forum Puts Trust at the Center of Crisis Media

Updated Category News Views 82

Rumours do not wait politely for a communications team to finish its meeting. That plain reality sat underneath Abdulla bin Mohammed bin Butti Al Hamed's keynote at Ajman Media Forum 2026, and it is a tougher point than the usual talk about reach, engagement, or flashy new technology. In a crisis, an information vacuum gets filled fast, usually by somebody with no...

Continue Reading
RUDSAK Tests Premium Demand From Toronto to New York

Updated Category News Views 145

A coat rack on Bloor Street can tell a harsher story than a glossy expansion announcement. RUDSAK has opened a Toronto flagship at 55 Bloor Street West in the Manulife Centre and is preparing a boutique at American Dream outside New York City. This is a real step up in retail ambition for the Montréal luxury outerwear house, founded in 1994, and it deserves more than the...

Continue Reading
Shenzhen Three-Way Summit Puts Stability to the Test

Updated Category News Views 153

Three nuclear powers sharing a room in Shenzhen is the sort of headline that makes every risk desk sit upright, even when the paperwork remains thin. CGTN reports that Chinese President Xi Jinping, Russian President Vladimir Putin and U.S. President Donald Trump met on November 19, 2026, in an unprecedented trilateral summit and issued a Declaration toward Peace. That is...

Continue Reading

Top 5 Most Recently Viewed Articles

OmniPathology Partners with Gestalt to Enhance Diagnostic Equity

Updated Category News Views 159

OmniPathology Joins Forces with Gestalt for a Digital Revolution In an exciting development for the medical field, OmniPathology has chosen Gestalt as its strategic partner to innovate their digital pathology solutions. This collaboration signifies a step towards modernizing diagnostic workflows, ultimately enhancing the quality of healthcare services. Transforming...

Continue Reading
Kneat Partners with Leading Global Therapeutics Firm

Updated Category News Views 232

Kneat Partners with Leading Global Therapeutics Firm Kneat.com, inc. (TSX: KSI) (OTCQX: KSIOF), known for its expertise in digitizing and automating essential validation and quality processes, has secured a significant three-year Master Services Agreement with a prominent global therapeutics company. This collaboration aims to fully digitize the validation processes of...

Continue Reading
Exploring Dividend Opportunities with Pfizer and Bristol Myers Squibb

Updated Category News Views 84

The Current State of Dividend Stocks The past year has been quite eventful for stock markets, showcasing significant gains across various indices. However, this surge has made it more difficult for investors to find stocks that are reasonably priced. With the S&P 500 index seeing a substantial increase, identifying attractive buying opportunities has become a challenge...

Continue Reading
Magna International's Impressive Quarterly Progress and Future Outlook

Updated Category News Views 403

Overview of Magna International's Second Quarter Results Magna International Inc. reported robust performance for the second quarter of 2025, showcasing resilience in the face of industry challenges. The company achieved $10.6 billion in sales, despite a 3% decline compared to the previous year, attributed mainly to lower light vehicle production in various markets....

Continue Reading
Guardian Capital Unveils Projected Non-Cash Distributions for ETFs

Updated Category News Views 265

Guardian Capital Announces Estimated 2025 Distributions Guardian Capital LP is pleased to share its estimated annual non-cash year-end distributions for the 2025 tax year related to the Guardian Capital ETFs. Please note that these estimates were made as of mid-November, and while they provide valuable insight, the final amounts may change before the tax year-end in late...

Continue Reading